Hyperprolactinaemia and DNA synthesis in the pituitary gland of the rat

1983 ◽  
Vol 97 (1) ◽  
pp. 65-74 ◽  
Author(s):  
J. A. Burdman ◽  
M. T. Calabrese ◽  
R. M. MacLeod

Hyperprolactinaemia produced in rats by the transplanted prolactin-secreting tumours MtTW15 and 7315a significantly (P<0·01) inhibited by 70% the incorporation of [3H]thymidine into the pituitary DNA of the host animals. The weight and the DNA content of the glands were significantly (P<0·01) reduced by 30%. The administration of haloperidol, a dopamine receptor blocking agent, to the tumour-bearing rats increased the suppressed DNA replication in the anterior pituitary glands by approximately 560% in the MtTW15-bearing rat and by 100% in the 7315a-bearing animals. Furthermore, injection of drugs which stimulate prolactin release either by blocking the synthesis of dopamine (α-methyl-p-tyrosine) or the re-uptake of dopamine (reserpine) stimulated DNA synthesis by 800 and 100% respectively in the anterior pituitary gland of rats bearing the MtTW15 tumour. In contrast, lisuride, a dopamine agonist, significantly inhibited the incorporation of [3H]thymidine into the DNA of the pituitary gland of normal but not hyperprolactinaemic rats. Chronically administered oestrogens to hyperprolactinaemic rats increased the weight (100%), DNA content (31%), incorporation of [3H]thymidine into DNA (680%) and synthesis and release of prolactin (300%) in the pituitary gland. The incorporation of [3H]thymidine into tumour DNA was several times higher than in the pituitary gland of the host animal and was not significantly modified by any of the above treatments. Likewise the hyperprolactinaemia of the tumour-bearing rats was not significantly changed. In conclusion, we have shown that hyperprolactinaemia inhibits DNA synthesis in the anterior pituitary gland and this inhibition can be reversed completely by a dopamine receptor blocking agent and by hypothalamic dopamine depleting drugs. We propose that dopamine regulates, either directly or indirectly, DNA synthesis in the lactotrophs of the pituitary gland, which may be responsive to negative feedback mechanisms.

Life Sciences ◽  
1984 ◽  
Vol 34 (3) ◽  
pp. 239-246 ◽  
Author(s):  
M. Mikuni ◽  
G.A. Gudelsky ◽  
M. Simonovic ◽  
H.Y. Meltzer

1981 ◽  
Vol 101 (3) ◽  
pp. 1052-1056 ◽  
Author(s):  
Marek Pawlikowski ◽  
Jolanta Kunert-Radek ◽  
Andrzej Lewiński ◽  
Ewa Karasek

1984 ◽  
Vol 33 (12) ◽  
pp. 1981-1988 ◽  
Author(s):  
Brian F. Kilpatrick ◽  
Marc G. Caron

1978 ◽  
Vol 79 (2) ◽  
pp. 245-246 ◽  
Author(s):  
M. PAWLIKOWSKI ◽  
J. KUNERT-RADEK ◽  
H. STĘPIEŃ

Department of Experimental Endocrinology, Institute of Endocrinology, Medical Academy of Łódź, Dr Sterling sir. 3, 91–425 Łódź, Poland (Received 22 May 1978) Lloyd, Meares & Jacobi (1975) observed inhibition of mitotic activity in the anterior pituitary gland by the dopamine receptor agonist, bromocriptine, in oestrogen-treated male rats. This observation has been confirmed in our laboratory (Stępień, Wolaniuk & Pawlikowski, 1978). Suppression of mitotic activity in the pars intermedia of the rat pituitary gland by bromocriptine has also been observed (Rychter & Stępień, 1977). Furthermore, it has been found that the dopamine receptor blocker, pimozide, enhances mitotic activity in the rat anterior pituitary gland (Stępień et al. 1978). By the use of various ergot alkaloids, MacLeod & Lehmeyer (1973) succeeded in inhibiting the growth of transplantable rat pituitary tumours. There have also been observations suggesting an antiproliferative effect of bromocriptine on human pituitary tumours (Wass, Thorner, Morris, Rees, Mason, Jones &


Sign in / Sign up

Export Citation Format

Share Document